title: South Africa's poor warfarin control raises questions of benefit above other anticoagulant therapies in atrial fibrillation.
authors: J
authors: J
authors: Aalbers
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D001777:Blood Coagulation / Q000187:drug effects; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D019934:International Normalized Ratio; D018570:Risk Assessment; D013019:South Africa; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D014859:Warfarin